Media Coverage

Media Coverage

Read how VistaGen’s intention to revolutionize mental health medicine is causing a buzz in the media.

STAT logo image
CBC Group sets up AffaMed, EverInsight merger, eyes IPO
Read
psychiatric Times logo image
Benzodiazepines Hit With Boxed Warning by FDA
Read
BioWorld logo image
CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate
Read
HCP Live logo image
Michael Liebowitz, MD, VistaGen CNS Clinical and Regulatory Advisory Board Member and Pivotal Phase 3 Principal Investigator: The Mental Health Impact of COVID-19
Read
Life Science Leader logo image
The Future of Anxiety Treatment Will Be Drastically Different
Read
Applied Clinical Trials logo image
Pushing Late-Stage Treatments Forward in the Clinic
Read
Pharmaceutical Technology logo image
Treating social anxiety disorder: VistaGen and EverInsight collaborate in Asian markets
Read
Thepharmaletter logo image
VistaGen out-licenses rights to anxiety disorder candidate in Asia territories
Read
MD Magazine logo image
DocTalk Podcast: The Psychological Damage of the COVID-19 Pandemic
Read